Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of complementary 7-valent pneumococcal conjugate vaccine with or separate from Prevnar 13 in healthy infants
2020-005039-59Phase 2
- Sponsor
- Pfizer
- Start
- Mar 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pneumococcal 7-valent conjugate vaccine and Prevnar 13 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoint: Prompted local reactions within 7 days after each dose.
02
Drugs
pneumococcal 7-valent conjugate vaccinePrevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2020-005039-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005039-59.